Inmagene Biopharmaceuticals
IMA · Nasdaq · United States
Share price · IMA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IMA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026+21.9%
Nothing announced by IMA that day or the session before.
- 23 Oct 2026+4.3%
Nothing announced by IMA that day or the session before.
- 8 Oct 2026-7.6%
Nothing announced by IMA that day or the session before.
- 12 Aug 2026+6.8%
Nothing announced by IMA that day or the session before.
- 23 Jul 2026-6.7%
- 20 Jul 2026+6.5%
Nothing announced by IMA that day or the session before.
- 16 Jul 2026-9.3%
Nothing announced by IMA that day or the session before.
- 8 May 2026-10.5%
- 13 Apr 2026+23.4%
- 6 Apr 2026-8.5%
Nothing announced by IMA that day or the session before.
Share of unusual movement by asset
For each asset, the share of IMA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Olevaprubartevents and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 18% |
| Sessions with no dated event | — | 82% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | OX40Monoclonal antibody | Atopic Dermatitis |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $11M | $85M+ $42M short-term inv. | $16M-$9.5M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $6.7M | $95M+ $41M short-term inv. | $10M-$9.1M operating cash flow | report ↗ |
| 2026-Q1 | — | $6.0M | $117M | $11M | report ↗ |
| 2025-Q3 | — | $16M | $103M+ $39M short-term inv. | $25M-$27M operating cash flow | report ↗ |
| 2025-Q2 | — | $4.0M | $59M+ $37M short-term inv. | $2.8M-$3.4M operating cash flow | report ↗ |
| 2025-Q1 | $0.8M | $3.7M | $38M+ $77M short-term inv. | $8.6M-$11M operating cash flow | report ↗ |
| 2024-Q3 | $3.5M | $6.8M | $46M+ $93M short-term inv. | $10M-$8.9M operating cash flow | report ↗ |
| 2024-Q2 | — | $9.8M | $46M+ $101M short-term inv. | $14M-$13M operating cash flow | report ↗ |
| 2024-Q1 | — | $9.7M | $54M+ $105M short-term inv. | $16M-$18M operating cash flow | report ↗ |
| 2023-Q3 | $1.2M | $15M | $123M+ $76M short-term inv. | $17M-$20M operating cash flow | report ↗ |
| 2023-Q2 | $2.0M | $15M | $72M+ $86M short-term inv. | $17M-$18M operating cash flow | report ↗ |
| 2023-Q1 | $5.3M | $16M | $30M+ $108M short-term inv. | $14M-$20M operating cash flow | report ↗ |
| 2022-Q3 | $6.4M | $19M | $68M+ $107M short-term inv. | $17M-$17M operating cash flow | report ↗ |
| 2022-Q2 | $0.4M | $15M | $49M+ $144M short-term inv. | $20M-$19M operating cash flow | report ↗ |
| 2022-Q1 | $3.4M | $14M | $48M+ $166M short-term inv. | $17M-$20M operating cash flow | report ↗ |
| 2021-Q3 | $3.8M | $13M | $247M | $15M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.8M | $29M | $95M+ $41M short-term inv. | $11M-$48M operating cash flow | report ↗ |
Inmagene Biopharmaceuticals reported revenue of $0.8M, down 77.1% YoY, R&D spend of $28.53M, down 7.6% YoY, cash and equivalents of $94.53M, and a net loss of $45.35M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $3.5M | $31M | $40M+ $85M short-term inv. | $12M-$46M operating cash flow | report ↗ |
| 2023-FY | $9.2M | $60M | $121M+ $56M short-term inv. | $17M-$80M operating cash flow | report ↗ |
| 2022-FY | $16M | $64M | $61M+ $97M short-term inv. | $17M-$74M operating cash flow | report ↗ |
| 2021-FY | $31M | $47M | $233M | $8.5M-$60M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($96K), 2 sales ($17K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-14 | Grant-Huerta Yanina · Chief Financial Officer | Award / grant | 65,000 | — | — | Form 4 |
| 2026-08-14 | Yarema Kristin · director, Chief Executive Officer | Award / grant | 254,800 | — | — | Form 4 |
| 2026-08-14 | Grant-Huerta Yanina · Chief Financial Officer | Award / grant | 39,000 | — | — | Form 4 |
| 2026-08-14 | Yarema Kristin · director, Chief Executive Officer | Award / grant (derivative) | 137,200 | — | — | Form 4 |
| 2026-08-14 | Grant-Huerta Yanina · Chief Financial Officer | Award / grant (derivative) | 56,000 | — | — | Form 4 |
| 2026-08-14 | Yarema Kristin · director, Chief Executive Officer | Award / grant (derivative) | 250,000 | — | — | Form 4 |
| 2026-07-25 | Yarema Kristin · director, Chief Executive Officer | Option exercise | 38,376 | — | — | Form 4 |
| 2026-07-25 | Yarema Kristin · director, Chief Executive Officer | Other (see filing) | 115,129 | — | — | Form 4 |